[Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
Matveev
B P
BP
Bukharkin
B V
BV
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000813:Anilides / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D017273:Goserelin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013607:Tablets; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D013607:Tablets; D014105:Tosyl Compounds; D017273:Goserelin; D013739:Testosterone; C053541:bicalutamide; D017430:Prostate-Specific Antigen
Predvaritel'nye rezul'taty primeneniia kasodeksa u bol'nykh gormonorezistentnym rakom predstatel'noĭ zhelezy.